{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:30:29Z","timestamp":1756384229647,"version":"3.44.0"},"reference-count":23,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,5,29]]},"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>While neuroleptic malignant syndrome (NMS) is typically characterised by delirium, motor rigidity, fever and dysautonomia, the syndrome is not pathognomonic, and NMS remains a diagnosis of exclusion. Here, we describe the case of a 44-year-old woman, with no relevant psychiatric history, admitted to a nephrology unit due to acute renal failure. After administration of antipsychotics, she presented with mental status alteration, generalised tremor, rigidity and autonomic nervous system dysfunction. Fever and rhabdomyolysis, however, were not prominent, and NMS was not considered initially in the differential diagnosis. The resulting delay in diagnosis, with continued administration of antipsychotics, led to progressive clinical deterioration. Once NMS was considered, however, antipsychotics were withdrawn and the patient was treated with electroconvulsive therapy (ECT), followed by administration of a dopamine receptor agonist, with close to full remission of all symptoms. Importantly, during outpatient follow-up, sustained mild and asymmetric tremor and rigidity was noted, leading to a diagnosis of Parkinson\u2019s disease. While this raises questions regarding differential diagnosis between NMS in Parkinson\u2019s disease, versus worsening of Parkinson\u2019s disease due to antipsychotic treatment, the former is supported by the acute and rapidly progressive onset of exuberant autonomic dysfunction and clouded conscience, after administration of a neuroleptic. Ultimately, a definitive distinction between these two alternatives for diagnosis of the inaugural neurological presentation in this patient is not possible. Nevertheless, we believe this case illustrates that NMS can be easily missed, particularly in atypical cases, delaying appropriate treatment, and that a flexible multimodal treatment approach, involving ECT, should be considered for complex clinical cases. Furthermore, it also underlines the importance of post-NMS follow-up, to investigate underlying neurological or medical disorders, particularly in those patients who do not have a full recovery.<\/jats:p>","DOI":"10.1136\/bcr-2018-225840","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T05:35:11Z","timestamp":1560836111000},"page":"e225840","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Neuroleptic malignant syndrome: a concealed diagnosis with multitreatment approach"],"prefix":"10.1136","volume":"12","author":[{"given":"Ana","family":"Velosa","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal"}]},{"given":"Ant\u00f3nio","family":"Neves","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal"},{"name":"Department of Psychiatry and Mental Health, NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal"}]},{"given":"J Bernardo","family":"Barahona-Corr\u00eaa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal"},{"name":"Department of Psychiatry and Mental Health, NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal"},{"name":"Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal"}]},{"given":"Albino J","family":"Oliveira-Maia","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Mental Health, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal"},{"name":"Department of Psychiatry and Mental Health, NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal"},{"name":"Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal"}]}],"member":"239","published-online":{"date-parts":[[2019,6,17]]},"reference":[{"key":"2025082803174506000_12.6.e225840.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30278-4"},{"key":"2025082803174506000_12.6.e225840.2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/85.1.129"},{"key":"2025082803174506000_12.6.e225840.3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/NDT.S118438","article-title":"Neuroleptic malignant syndrome: an easily overlooked neurologic emergency","volume":"13","author":"Oruch","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025082803174506000_12.6.e225840.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.1999.00630.x"},{"key":"2025082803174506000_12.6.e225840.5","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390090009002"},{"key":"2025082803174506000_12.6.e225840.6","unstructured":"Sadock BJ , Sadock VA . Kaplan and Sadock\u2019s synopsis of psychiatry: behavioral sciences\/clinical psychiatry: Lippincott Williams & Wilkins, 2015."},{"key":"2025082803174506000_12.6.e225840.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1996.tb09814.x"},{"key":"2025082803174506000_12.6.e225840.8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.4.366"},{"key":"2025082803174506000_12.6.e225840.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"2025082803174506000_12.6.e225840.10","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e3182420bfe"},{"key":"2025082803174506000_12.6.e225840.11","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198709001-00020"},{"key":"2025082803174506000_12.6.e225840.12","doi-asserted-by":"publisher","DOI":"10.1177\/1941875210386491"},{"key":"2025082803174506000_12.6.e225840.13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/JCP.0000000000000640","article-title":"A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome","volume":"37","author":"Gurrera","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"2025082803174506000_12.6.e225840.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/4938154","article-title":"The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson\u2019s Disease","volume":"2016","author":"Divac","year":"2016","journal-title":"Behav Neurol"},{"key":"2025082803174506000_12.6.e225840.15","doi-asserted-by":"publisher","DOI":"10.2217\/npy.14.3"},{"key":"2025082803174506000_12.6.e225840.16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.44.11.1020"},{"key":"2025082803174506000_12.6.e225840.17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.52.4.777","article-title":"Susceptibility to neuroleptic malignant syndrome in Parkinson\u2019s disease","volume":"52","author":"Ueda","year":"1999","journal-title":"Neurology"},{"key":"2025082803174506000_12.6.e225840.18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1192\/pb.bp.116.053736","article-title":"Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association","volume":"41","author":"Sarkar","year":"2017","journal-title":"BJPsych Bull"},{"key":"2025082803174506000_12.6.e225840.19","unstructured":"Taylor D , Barnes TRE , Young AH . The Maudsley Prescribing Guidelines in Psychiatry. 13th edn: Willey Blackwell, 2018."},{"key":"2025082803174506000_12.6.e225840.20","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001752","article-title":"A Case Report of Catatonia and Neuroleptic Malignant Syndrome With Multiple Treatment Modalities: short Communication and Literature Review","volume":"94","author":"Chiou","year":"2015","journal-title":"Medicine"},{"key":"2025082803174506000_12.6.e225840.21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/YIC.0000000000000059","article-title":"Successful treatment of hydroxyzine and dexclorfeniramine maleate in combination with electroconvulsive therapy in a neuroleptic malignant catatonia: a case report","volume":"30","author":"Fern\u00e1ndez-Corcuera","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"2025082803174506000_12.6.e225840.22","first-page":"471-3","article-title":"Drug resistant neuroleptic malignant syndrome and the role of electroconvulsive therapy","volume":"64","author":"Hashim","year":"2014","journal-title":"J Pak Med Assoc"},{"key":"2025082803174506000_12.6.e225840.23","first-page":"49","article-title":"Electroconvulsive therapy in drug resistant neuroleptic malignant syndrome","volume":"56","author":"Patel","year":"2008","journal-title":"J Assoc Physicians India"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-225840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:17:53Z","timestamp":1756376273000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-225840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,17]]},"published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1136\/bcr-2018-225840"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-225840","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}